Does FDA's Shift From Two Pivotal Trials to One Represent a Genuine Evolution?

Key Takeaways

• FDA now accepts single pivotal trial for certain oncology approvals
• Single‑trial pathway driven by urgent unmet need in life‑threatening cancers
• Chronic disease drugs still generally require two pivotal trials for robustness
• Post‑marketing studies become critical to monitor long‑term safety

Pulse Analysis

The Food and Drug Administration’s recent willingness to approve drugs based on a single pivotal trial marks a subtle but meaningful shift in its evidentiary standards. As former FDA Oncology Division Director Harpreet Singh explains, the change is less a revolution than an evolution, reflecting decades‑long practice in rare oncology where patient mortality during trials necessitates faster pathways. By treating a single, well‑controlled study as “adequate and well‑controlled,” regulators aim to balance rapid access with residual risk, deferring broader safety profiling to the post‑marketing phase.

In oncology, especially for rare cancers, the single‑trial approach can accelerate life‑saving treatments. Sponsors benefit from reduced development costs and shorter timelines, while patients gain earlier access to innovative therapies. However, the reliance on one dataset amplifies statistical uncertainty and places greater weight on trial design, endpoint selection, and patient selection criteria. Consequently, the FDA increasingly mandates rigorous post‑approval commitments, such as real‑world evidence collection and phase‑IV studies, to fill gaps in long‑term efficacy and safety.

The paradigm does not extend uniformly to chronic conditions like diabetes, multiple sclerosis, or cardiovascular disease, where therapies are used long‑term by large populations. Here, two pivotal trials remain the norm to address variability, power, and heterogeneity concerns. Industry strategists must therefore tailor development programs, allocating resources to meet higher evidentiary thresholds for chronic indications while leveraging the single‑trial flexibility for high‑unmet‑need oncology products. As the FDA continues to refine its risk‑benefit calculus, the balance between accelerated access and comprehensive data will shape future drug pipelines.